These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 26183545)
21. Bioassays and In Silico Methods in the Identification of Human DNA Topoisomerase IIα Inhibitors. Bergant K; Janezic M; Perdih A Curr Med Chem; 2018; 25(28):3286-3318. PubMed ID: 29508675 [TBL] [Abstract][Full Text] [Related]
22. Biophysical and molecular docking studies of naphthoquinone derivatives on the ATPase domain of human topoisomerase II. Boonyalai N; Sittikul P; Pradidphol N; Kongkathip N Biomed Pharmacother; 2013 Mar; 67(2):122-8. PubMed ID: 23089478 [TBL] [Abstract][Full Text] [Related]
23. Recent advances in the development of catalytic inhibitors of human DNA topoisomerase IIα as novel anticancer agents. Pogorelčnik B; Perdih A; Solmajer T Curr Med Chem; 2013; 20(5):694-709. PubMed ID: 23210851 [TBL] [Abstract][Full Text] [Related]
24. Substituted 4,5'-Bithiazoles as Catalytic Inhibitors of Human DNA Topoisomerase IIα. Bergant Loboda K; Janežič M; Štampar M; Žegura B; Filipič M; Perdih A J Chem Inf Model; 2020 Jul; 60(7):3662-3678. PubMed ID: 32484690 [TBL] [Abstract][Full Text] [Related]
25. Synthesis, biological evaluation, and molecular docking study of 3-(3'-heteroatom substituted-2'-hydroxy-1'-propyloxy) xanthone analogues as novel topoisomerase IIα catalytic inhibitor. Jun KY; Lee EY; Jung MJ; Lee OH; Lee ES; Park Choo HY; Na Y; Kwon Y Eur J Med Chem; 2011 Jun; 46(6):1964-71. PubMed ID: 21419530 [TBL] [Abstract][Full Text] [Related]
26. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs. Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287 [TBL] [Abstract][Full Text] [Related]
27. Polyamine-containing etoposide derivatives as poisons of human type II topoisomerases: Differential effects on topoisomerase IIα and IIβ. Oviatt AA; Kuriappan JA; Minniti E; Vann KR; Onuorah P; Minarini A; De Vivo M; Osheroff N Bioorg Med Chem Lett; 2018 Sep; 28(17):2961-2968. PubMed ID: 30006062 [TBL] [Abstract][Full Text] [Related]
28. A chromenone analog as an ATP-competitive, DNA non-intercalative topoisomerase II catalytic inhibitor with preferences toward the alpha isoform. Park S; Hwang SY; Shin J; Jo H; Na Y; Kwon Y Chem Commun (Camb); 2019 Nov; 55(85):12857-12860. PubMed ID: 31598611 [TBL] [Abstract][Full Text] [Related]
29. Novel trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-ones act as covalent poisons of human topoisomerase IIα. Infante Lara L; Sledge A; Laradji A; Okoro CO; Osheroff N Bioorg Med Chem Lett; 2017 Feb; 27(3):586-589. PubMed ID: 27998679 [TBL] [Abstract][Full Text] [Related]
30. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Wu CC; Li TK; Farh L; Lin LY; Lin TS; Yu YJ; Yen TJ; Chiang CW; Chan NL Science; 2011 Jul; 333(6041):459-62. PubMed ID: 21778401 [TBL] [Abstract][Full Text] [Related]
31. HU-331 is a catalytic inhibitor of topoisomerase IIα. Regal KM; Mercer SL; Deweese JE Chem Res Toxicol; 2014 Dec; 27(12):2044-51. PubMed ID: 25409338 [TBL] [Abstract][Full Text] [Related]
32. 3-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIα catalytic inhibitor with low DNA damage. Park SE; Chang IH; Jun KY; Lee E; Lee ES; Na Y; Kwon Y Eur J Med Chem; 2013 Nov; 69():139-45. PubMed ID: 24013413 [TBL] [Abstract][Full Text] [Related]
33. Two-Mechanism Model for the Interaction of Etoposide Quinone with Topoisomerase IIα. Gibson EG; King MM; Mercer SL; Deweese JE Chem Res Toxicol; 2016 Sep; 29(9):1541-8. PubMed ID: 27533850 [TBL] [Abstract][Full Text] [Related]
34. The p53 tumor suppressor stimulates the catalytic activity of human topoisomerase IIalpha by enhancing the rate of ATP hydrolysis. Kwon Y; Shin BS; Chung IK J Biol Chem; 2000 Jun; 275(24):18503-10. PubMed ID: 10764786 [TBL] [Abstract][Full Text] [Related]
35. Examination of the Impact of Copper(II) α-(N)-Heterocyclic Thiosemicarbazone Complexes on DNA Topoisomerase IIα. Wilson JT; Jiang X; McGill BC; Lisic EC; Deweese JE Chem Res Toxicol; 2016 Apr; 29(4):649-58. PubMed ID: 26982206 [TBL] [Abstract][Full Text] [Related]
36. D11, a novel glycosylated diphyllin derivative, exhibits potent anticancer activity by targeting topoisomerase IIα. Gui M; Shi DK; Huang M; Zhao Y; Sun QM; Zhang J; Chen Q; Feng JM; Liu CH; Li M; Li YX; Geng M; Ding J Invest New Drugs; 2011 Oct; 29(5):800-10. PubMed ID: 20336347 [TBL] [Abstract][Full Text] [Related]
37. Differential Targeting of Human Topoisomerase II Isoforms with Small Molecules. Mariani A; Bartoli A; Atwal M; Lee KC; Austin CA; Rodriguez R J Med Chem; 2015 Jun; 58(11):4851-6. PubMed ID: 25945730 [TBL] [Abstract][Full Text] [Related]
38. 11-Phenylundeca-5Z,9Z-dienoic Acid: Stereoselective Synthesis and Dual Topoisomerase I/IIα Inhibition. D'yakonov VA; Dzhemileva LU; Makarov AA; Mulyukova AR; Baevd DS; Khusnutdinova EK; Tolstikova TG; Dzhemilev UM Curr Cancer Drug Targets; 2015; 15(6):504-10. PubMed ID: 25968900 [TBL] [Abstract][Full Text] [Related]
39. Impact of the C-terminal domain of topoisomerase IIalpha on the DNA cleavage activity of the human enzyme. Dickey JS; Osheroff N Biochemistry; 2005 Aug; 44(34):11546-54. PubMed ID: 16114891 [TBL] [Abstract][Full Text] [Related]
40. Pharmacophore Hybridization To Discover Novel Topoisomerase II Poisons with Promising Antiproliferative Activity. Ortega JA; Riccardi L; Minniti E; Borgogno M; Arencibia JM; Greco ML; Minarini A; Sissi C; De Vivo M J Med Chem; 2018 Feb; 61(3):1375-1379. PubMed ID: 29077404 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]